Celsion (CLSN) Getting Favorable Press Coverage, Report Shows

Media headlines about Celsion (NASDAQ:CLSN) have trended positive recently, according to Accern Sentiment. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Celsion earned a coverage optimism score of 0.28 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 47.0792628645572 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Several research analysts have commented on the stock. Zacks Investment Research downgraded shares of Celsion from a “buy” rating to a “hold” rating in a report on Tuesday, October 17th. Oppenheimer assumed coverage on shares of Celsion in a report on Tuesday, November 21st. They set an “outperform” rating and a $9.00 price objective for the company. ValuEngine downgraded shares of Celsion from a “sell” rating to a “strong sell” rating in a report on Wednesday, November 15th. Finally, Maxim Group raised shares of Celsion from a “hold” rating to a “buy” rating and set a $7.00 price objective for the company in a report on Wednesday, October 4th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. Celsion has an average rating of “Buy” and an average target price of $11.90.

Celsion (NASDAQ CLSN) remained flat at $$2.64 on Friday. 305,100 shares of the stock traded hands, compared to its average volume of 597,825. Celsion has a one year low of $1.24 and a one year high of $7.56. The firm has a market cap of $42.40, a P/E ratio of -0.45 and a beta of 1.22.

Celsion (NASDAQ:CLSN) last announced its quarterly earnings results on Tuesday, November 14th. The biotechnology company reported ($0.39) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.56) by $0.17. Celsion had a negative net margin of 4,292.80% and a negative return on equity of 282.94%. equities analysts predict that Celsion will post -2.46 EPS for the current year.

WARNING: This news story was first reported by Ticker Report and is the property of of Ticker Report. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3146192/celsion-clsn-getting-favorable-press-coverage-report-shows.html.

About Celsion

Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).

Insider Buying and Selling by Quarter for Celsion (NASDAQ:CLSN)

Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.